79 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
, and IV tramadol, which is in Phase 3 clinical development for the management of acute post-operative pain in adults in a medically supervised healthcare … and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
healthcare laws and regulations;
the effects of competition for our product candidates and the potential for new products to emerge that provide
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
information privacy and security, and other healthcare laws and regulations;
the effects of competition for our product candidates and the potential for new … they relate to events, competitive dynamics, and healthcare, regulatory and scientific developments and depend on the economic circumstances that may
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit … claims, transparency, health information privacy and security, and other healthcare laws and regulations; the effects of competition for our product
8-K
EX-99.1
75y3xa4ogq5
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
1eczcz 6ole7k2lwmsc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B3
p8he2sep5 g1j6rfd0
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-99.1
i27auczznd0t95iha2s
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-99.1
mzdys5
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.2
y4vjf
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
8ih7rn
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
xlh5sfyomw0r
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
itd rdhq0m43t1ie
5 Oct 23
Free writing prospectus
5:05pm
FWP
ylm6biydt
3 Oct 23
Free writing prospectus
5:47pm